ST PHARM has expanded its production facility for oligonucleotides, which are used as raw materials for messenger ribonucleic acid (RNA) therapeutics. The company has set a goal of becoming the world's number one company in oligonucleotide contract development and manufacturing organization (CDMO) with its enhanced production capabilities.
ST PHARM announced on the 5th that it held a ceremony for the completion of the second oligonucleotide building at its Banwol campus in Ansan, Gyeonggi Province, on the 4th. This facility was built by Aveon Construction, which specializes in constructing facilities that meet current good manufacturing practices (cGMP).
The second oligonucleotide building covers an area of 10,900 square meters, stands 60 meters high, and has nine floors. Unlike the first oligonucleotide building, which is focused on large lines, this new facility is equipped with various lines ranging from small to large. The top two floors are designed as a "future area" space to respond to client requests. An automated factory equipment system and warehouse management system are also in operation.
The company noted that it has adopted new technologies, such as reusing waste heat for heating, a distillation system without cooling water, and extending filter lifetimes, to secure competitiveness regarding environmental, social responsibility, and corporate governance (ESG).
Through this completion, ST PHARM plans to strengthen its three core businesses: ▲ oligonucleotide CDMO ▲ production of raw materials for low-molecular-weight synthetic drugs ▲ and production of mRNA therapeutics utilizing its own platform.
Seong Mu-je, CEO of ST PHARM, said, "With the completion of the second oligonucleotide building, ST PHARM will further strengthen its customer-oriented mindset to respond more closely to the demands of various markets," adding, "Based on the spirit of 'opening a new path and creating the future,' all employees will strive to make this a life-saving innovative corporation."